Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints

Overview of attention for article published in Orphanet Journal of Rare Diseases, February 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 21 X posts from 18 X users, with an upper bound of 47,666 followers.

RT @eerr_es: Recommendations for the development of rare disease drugs using the accelerated approval pathway... https://t.co/h5onLyAHl9

RT @eerr_es: Recommendations for the development of rare disease drugs using the accelerated approval pathwa... https://t.co/wDlceOAN0h #Me…

Recommendations for the development of rare disease drugs using the accelerated approval pathway... https://t.co/h5onLyAHl9

Recommendations for the development of rare disease drugs using the accelerated approval pathwa... https://t.co/wDlceOAN0h #MedHuérfanos

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 17 additional X posts.